StockData
Viridian Therapeutics, Inc.DE logo

Viridian Therapeutics, Inc.DE (VRDN) stock

VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30260% above fair value
$29.96−1.48 (-4.71%)

Close on Nov 20, 2026Market cap $3.39BP/E –Yield –

Viridian Therapeutics, Inc.DE revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Viridian Therapeutics, Inc.DE's revenue for the twelve months ending Jun 30, 2026 was $71.13M, up 23220.3% year over year. For fiscal 2025 it was $70.85M, up 23359.9% from the year before. Over ten years it grew 39.5% a year on average. The highest annual figure on record is $70.85M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$70.85M+23359.9%
FY2024Dec 31, 2024$302.00K-3.8%
FY2023Dec 31, 2023$314.00K-82.3%
FY2022Dec 31, 2022$1.77M-40.2%
FY2021Dec 31, 2021$2.96M+182.2%
FY2020Dec 31, 2020$1.05M-76.5%
FY2019Dec 31, 2019$4.46M-46.8%
FY2018Dec 31, 2018$8.39M+109.5%
FY2017Dec 31, 2017$4.00M+15.1%
FY2016Dec 31, 2016$3.48M+37.0%
FY2015Dec 31, 2015$2.54M-60.9%
FY2014Dec 31, 2014$6.48M+18.1%
FY2013Dec 31, 2013$5.49M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$284.00K+278.7%
Q1 FY2026Mar 31, 2026$141.00K+95.8%
Q4 FY2025Dec 31, 2025$132.00K+83.3%
Q3 FY2025Sep 30, 2025$70.57M+81958.1%
Q2 FY2025Jun 30, 2025$75.00K+4.2%
Q1 FY2025Mar 31, 2025$72.00K0.0%
Q4 FY2024Dec 31, 2024$72.00K0.0%
Q3 FY2024Sep 30, 2024$86.00K+19.4%
Q2 FY2024Jun 30, 2024$72.00K0.0%
Q1 FY2024Mar 31, 2024$72.00K-26.5%
Q4 FY2023Dec 31, 2023$72.00K-31.4%
Q3 FY2023Sep 30, 2023$72.00K-94.0%
Q2 FY2023Jun 30, 2023$72.00K-71.9%
Q1 FY2023Mar 31, 2023$98.00K-54.6%
Q4 FY2022Dec 31, 2022$105.00K-50.9%
Q3 FY2022Sep 30, 2022$1.20M+474.5%
Q2 FY2022Jun 30, 2022$256.00K-76.5%
Q1 FY2022Mar 31, 2022$216.00K-85.1%
Q4 FY2021Dec 31, 2021$214.00K+296.3%
Q3 FY2021Sep 30, 2021$208.00K–
Q2 FY2021Jun 30, 2021$1.09M+548.8%
Q1 FY2021Mar 31, 2021$1.45M+75.2%
Q4 FY2020Dec 31, 2020$54.00K-93.9%
Q3 FY2020Sep 30, 2020$0-100.0%
Q2 FY2020Jun 30, 2020$168.00K-93.3%
Q1 FY2020Mar 31, 2020$828.00K+122.6%
Q4 FY2019Dec 31, 2019$880.00K+84.9%
Q3 FY2019Sep 30, 2019$695.00K-26.4%
Q2 FY2019Jun 30, 2019$2.51M+15.2%
Q1 FY2019Mar 31, 2019$372.00K-92.2%
Q4 FY2018Dec 31, 2018$476.00K-60.1%
Q3 FY2018Sep 30, 2018$944.00K-42.1%
Q2 FY2018Jun 30, 2018$2.18M+203.9%
Q1 FY2018Mar 31, 2018$4.78M+935.5%
Q4 FY2017Dec 31, 2017$1.19M+134.2%
Q3 FY2017Sep 30, 2017$1.63M+74.3%
Q2 FY2017Jun 30, 2017$718.00K–
Q1 FY2017Mar 31, 2017$462.00K–
Q4 FY2016Dec 31, 2016$509.00K–
Q3 FY2016Sep 30, 2016$936.00K–

More Viridian Therapeutics, Inc.DE figures

See a number that looks wrong?